Scienture Holdings, Inc. · NASDAQ:SCNX
Scienture — Investor Presentation (October 2024)
16 slides from Scienture's investor presentation, Oct 8, 2024
Slide 1: Scienture Holdings, Inc. Investor Presentation
383 SCIENTURE HOLDINGS, INC. Investor Presentation NASDAQ; SCNX October 2024
Slide 2: Forward-looking statements
The information set fr rin contains farwanooking stems within the fer sects lw, ining th safe hrbor provisions of the Private Sects Litigation Reform Ast of 1995, Farnantlosking sstements include all statements hat do mot ret soley to hint o ume fit, inelang, but ot ied stems regarding fate operatio
Slide 3: About Scienture Holdings, Inc.
About SCIENTURE HOLDINGS, INC. SCIENTURE HOLDINGS, Inc is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Our products in development are across therapeutic a
Slide 4: Divisions of Scienture Holdings
Divisions of SCIENTURE HOLDINGS Specialty Pharmaceuticals, Pharmaceutical distributor & Supporting Subsidiaries an Specialty Brand Pharmaceuticals 333 scienture® Specialty Pharmaceuticals Value-added brand product portfolio developed by employing unique technology concepts that bring enhanced value
Slide 5: Executive Management
Executive Management — ] \ Suren Ajjarapu Prashant Patel, Shankar Hariharan ‘Narasimhan Mani Rahul Surana Chairman & President, COO | CEO President EvPand COO CEO and Interim CFO Scienture, LLC Scienture, LLC Scienture, LLC Mr. Ajjarapu has served as Mr. Patel has served as Dr. Hariharan has over Dr
Slide 6: Specialty Pharmaceuticals
SPECIALTY PHARMACEUTICALS
Slide 7: About Scienture, LLC
About Scienture, LLC 339 Specialty pharmaceutical company with an innovative portfolio of brand products + Awholly owned subsidiary of SCIENTURE HOLDINGS, Inc. (NASDAQ: SCNX) * Scienture, Inc. (“Scienture”) announced the closing of a business combination with TRKADE HEALTH, INC. (“TRxADE”) (Nasdaq:
Slide 8: Product Portfolio
Product Portfolio* Near Term Commercial and Focused Pipeline in Development** Human Studies NDA/BLASubmission Anticipated Projected Market Indication IDA/BU ip i Timeline launch Opportunity Phase 2 ‘SCN-104 — CNS/Pain Drug device combination for convenient sf injection Ghee aati Seni ‘SCN-106- CVS B
Slide 9: Commercial Go To Market Capabilities
Commercial Go To Market Capabilities Experienced internal leadership team managing all aspects of Product Launches + Field Teams, Virtual Reps and Digital Omnichannel Marketing «Territory Mapping and HCP Segmentation + Regional focus and top decile coverage + Primary Research, Payer Value Propositio
Slide 10: Rx Distribution
10 Rx DISTRIBUTION
Slide 11: Distribution and Logistics Operations
afl Distribution and Logistics Operations 333 eo Integra Pharma Solutions is the pharmaceutical supplier of choice for healthcare organizations of all sizes supplying pharmaceuticals nationwide. ¢Currently in VAWD (Drug Distributor Accreditation) Pending Status *Supplies pharmaceuticals, diabetic su
Slide 12: Key Takeaways
12 Key Takeaways NASDAQ:SCNX SCIENTURE HOLDINGS is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Our products in development are across therapeutic areas, i
Slide 13: Board of Directors
Board of Directors 33 Suren Ajarapu, Chairman of the Board Donald G. Fell Mr. Ajjarapu has served as Chairman of the Board, Chief Executive Officer and ‘An economist who formerly headed the Executive and Secretary since our acquisition of Trxade Group, Inc. Mr. Ajjarapu holds an MS in Professional E
Slide 14: Contact Us
14 Contact Us SCIENTURE HOLDINGS, INC. 2420 Brunello Trace Lutz, FL 34558 (800) 261-0281 www.scienture.com
Slide 15: Appendix: Consolidated Balance Sheet
Appendix: Consolidated Balance Sheet Summai ro forma _con: Cash Notes receivable - related party ‘Current assets Goodwill and intangibles Investments Total assets ‘Accounts payable and accrued liabilities Warrant liability Convertible notes Development agreement liability Stockholders’ equity Total
Slide 16: Appendix: Income Statement
Appendix: Income Statement ge 05 Summary pro forma consolidated income sheet data for YTD June 30, 2024 YTD June 30, 2024 Revenues s 18,699 Gross profit (703) Research and development 1,520,947 General and administrative 8,025,000 Termination fee 1,285,000 Other operating expenses 1,872,377 Non-oper
Scienture Holdings — Investor Presentation (October 2024) on 6ix